Understanding bleeding risks in people with factor XI deficiency
Official title: Interdisciplinary approach to elucidate modifiers of bleeding phenotype in factor XI deficiency
Funded at Univ of North Carolina Chapel Hill · NIH-11089557 · Data updated 2026-11-12
This study is looking into why some people with factor XI deficiency bleed more than others, and it aims to create better tests to help predict who might be at risk, so that treatments can be improved for those affected.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project start | May 15, 2024 |
| Project end | April 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $606,023 |
| NIH project number | 5R01HL173974-02 |
| Project ID | NIH-11089557 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with factor XI deficiency, particularly those experiencing variable bleeding symptoms.
✕Less likely to help
Patients with bleeding disorders unrelated to factor XI deficiency may not benefit from this research.
What this research studies
This research investigates the reasons behind varying bleeding risks in individuals with factor XI deficiency, a genetic disorder affecting blood clotting. By analyzing blood samples from well-characterized patients, the study aims to develop specialized assays that can accurately predict who is at risk of excessive bleeding. The approach combines laboratory techniques and computational modeling to uncover the biological mechanisms influencing bleeding. Ultimately, the goal is to improve treatment strategies for both bleeding and thrombosis in affected individuals.
Why it matters
Potential benefit: If successful, this research could lead to better prediction and management of bleeding risks for patients with factor XI deficiency.
How similar studies have gone: Previous research has shown promise in understanding bleeding risks in related conditions, suggesting that this approach could yield valuable insights.
Where this research is happening
-
Univ of North Carolina Chapel Hill
Chapel Hill, United States Active
Researchers
- Principal investigator: Wolberg, Alisa S. — Univ of North Carolina Chapel Hill
- Study coordinator: Wolberg, Alisa S.
Related research
Other NIH-funded projects on the same topics.
-
Direct measurement of RhD sensitization after early-pregnancy bleeding
This study tests how often Rh immunoglobulin given after bleeding in early pregnancy prevents RhD sensitization in pregnant people.
-
EpiMAX: a new injectable gel that stops GI bleeding quickly and for days
A new injectable hydrogel with epinephrine-loaded microparticles is designed to plug GI bleeds and provide immediate and lasting hemostasis for about 72 hours.
-
Dynamic risk tools to prevent blood clots and bleeding in cancer patients
A new AI-based approach will predict who among people with cancer starting treatment is at higher risk for blood clots or dangerous bleeding, helping doctors tailor preventive care.
-
Bleeding and Platelet Problems in Ehlers-Danlos Syndrome
This NIH grant looks at why people with Ehlers-Danlos syndrome bleed more and how platelet function is involved, with goals that could lead to better care during surgery or emergencies.
-
Long-acting RNA therapy to control fibrinolysis and reduce bleeding
A new RNA treatment delivered in lipids aims to slow down fibrinolysis and lessen bleeding for people with bleeding disorders or severe hemorrhage.
-
Thrombosis and Bleeding Risk in Medical Inpatients
A patient-facing program to better predict who is at risk for blood clots or bleeding during and after hospital stays, and to tailor prevention accordingly.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.